Dispensary data discrepancies spark call for robust auditing system in cannabis industry

In a recent public comment meeting held by the Oklahoma Medical Marijuana Authority (OMMA), concerns were raised about the accuracy of cannabis potency testing at dispensaries. As attendees gathered in the meeting room, the atmosphere was charged with a mix of curiosity and apprehension regarding the integrity of marijuana products available to consumers.

One speaker, Mr. Wilson, highlighted a significant issue: discrepancies in potency numbers between what is advertised by dispensaries and what is actually tested. He pointed out that consumers might find a variance of 10 to 12 percent in potency readings, leaving them uncertain about the source of the discrepancy. "Is it the grower? Did it happen to the lab? Is it how the dispensary is holding it?" he questioned, emphasizing the complexity of the supply chain and the various factors that could influence these numbers.

Wilson advocated for a more robust auditing system to address these anomalies. He suggested that while the sample size of tested products might not be the issue, a systematic approach to auditing could help clarify where discrepancies arise. He proposed that a range of 15 to 20 percent should be acceptable, but anything beyond that should trigger further investigation.

As the meeting progressed, it became clear that the topic of testing accuracy is not just a technical concern but one that affects consumer trust and safety in the burgeoning medical marijuana market. The discussions underscored the need for transparency and accountability among growers, labs, and dispensaries.

The meeting concluded with a sense of urgency for the OMMA to consider these insights as they work towards ensuring the integrity of medical marijuana products in Oklahoma. As the industry continues to evolve, the call for rigorous standards and practices remains a priority for both regulators and consumers alike.